A+ A A- Skip to main content
20-Nov-25 SENSEX 85,632.68[ 446.21 ]Adani Ports 1,490.90 [ 7.20 ]Asian Paints 2,859.15 [ -34.70 ]Axis Bank 1,285.25 [ 15.20 ]Bajaj Finance 1,028.50 [ 22.95 ]Bajaj Finserv 2,096.20 [ 46.10 ]Bharat Electron 423.00 [ -0.40 ]Bharti Airtel 2,159.45 [ -1.85 ]Eternal Ltd 307.00 [ 0.50 ]HCL Technologies 1,645.35 [ -17.65 ]HDFC Bank 1,008.80 [ 14.15 ]Hind. Unilever 2,429.10 [ -11.65 ]ICICI Bank 1,382.90 [ -0.20 ]Infosys 1,536.75 [ -4.50 ]ITC 405.50 [ 1.95 ]Kotak Mah. Bank 2,097.10 [ -9.00 ]Larsen & Toubro 4,037.70 [ 18.40 ]M & M 3,716.00 [ -6.20 ]Maruti Suzuki 15,799.40 [ 40.40 ]NTPC 326.75 [ 0.10 ]Power Grid Corpn 277.30 [ 2.05 ]Reliance Industr 1,549.10 [ 30.45 ]SBI 981.70 [ -0.75 ]Sun Pharma.Inds. 1,777.85 [ -6.30 ]Tata Motors PVeh 359.75 [ -1.15 ]Tata Steel 172.45 [ -0.65 ]TCS 3,145.75 [ -1.45 ]Tech Mahindra 1,456.70 [ 18.50 ]Titan Company 3,901.20 [ -31.55 ]Trent 4,388.85 [ 30.75 ]UltraTech Cem. 11,754.70 [ 89.80 ]
 
As on 19-Nov- 2025
Can Fin Homes

CARE Ratings (CareEdge Ratings) has reaffirmed ratings of long-term bank facilities and debt instruments of Can Fin Homes (CFHL) at CARE AAA+; Stable. Reaffirmation continues to factor CFHL's strong parentage, with Canara Bank (rated CARE AAA; Stable) as the primary shareholder holding 29.99% as on 30 September 2025. The parent provides board level oversight, strategic guidance and shared brand franchise. Despite its modest shareholding, Canara Bank considers CFHL a strategically important entity and has reiterated its commitment to provide support while maintaining its equity stake.

Supported by its parentage and track record, CFHL enjoys strong financial flexibility, enabling it to raise funds from diversified sources at competitive rates. Ratings also reflect CFHL's relatively low-risk loan portfolio, with a dominant share of salaried borrowers, its continued healthy financial performance, stable profitability, strong asset quality, and adequate capitalisation levels. These strengths outweigh credit challenges arising from high leverage, regional concentration and competitive housing finance segment.

Fynx Capital

Fynx Capital announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 11 December 2025.

Transchem

Transchem will hold a meeting of the Board of Directors of the Company on 21 November 2025.

Marksans Pharma

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.

 Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.

Simplex Castings

Simplex Castings has received a fabrication order worth Rs.11.76 crore from Bharat Heavy Electricals, Trichy and fabrication order worth Rs.80.73 lakhs from Paharpur Cooling Towers.

1 2 3 4 5  ... 
Site Map  |  Disclaimer  |  Margin Files  | E-Contract Login  |  Fund Transfer
Back Office Login  
Useful Links :  NSE  |  BSE  |  CDSL  |   Scores   |  Investor Charter  |  EKYC  |  CDSL E-Voting  |  NSDL E-Voting   |  SMART ODR    
Registered Office
B-11, 3rd Floor, Plot-36, Tamarind House, Mudhana Shetty Marg, Hutatma Chowk, Fort, Mumbai - 400 001
Existing customers can send in their Grievances to : investorgrievance@ssbpl.net '/ response@ssbpl.nets
 Attention Investor  |   Terms of Use  |   Privacy Policy  |  Rules & Regulations  |  Investor Protection  |  BSE Investor Complaints
Statutory Charges  |  PMLA / AML Policy  |  CDSL DP Charges   |   Advisory for Investors   |   Bank Details - Shilpa Stock   |   Bank Details - Shikago Trade
AP Details – BSE |    AP Details – NSE   |   KYC Process-Individuals   |    KYC Process - Non Individuals
Online Investor Grievance Redressal  |    Investor Complaints Process Flow  |    Voluntary Freezing/Blocking  |   View Client Collateral Details
KRA Validation Process  |   Re-KYC/Closure  |    Risk Disclosure on Derivative  |   Valid UPI Handle
Validate your Mobile and Email with KRA: CVL KRA  |  KARVY KRA  |  DOTEX KRA  |  CAMS KRA
SEBI Registration Details:

Shilpa Stock Broker Pvt. Ltd.: INZ000201636 | IN-DP-487-2020 | Research Analyst: INH000000776 | BSE Enlistment No.-5047 Shikago Trade Pvt. Ltd.: INZ000042135

© Copyright 2011 All Rights Reserved.Shilpa Stock Broker Pvt. Ltd.
Designed, Developed and Powered by C-MOTS Infotech (ISO 9001:2015 certified)